ATE487484T1 - Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür - Google Patents

Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Info

Publication number
ATE487484T1
ATE487484T1 AT05812199T AT05812199T ATE487484T1 AT E487484 T1 ATE487484 T1 AT E487484T1 AT 05812199 T AT05812199 T AT 05812199T AT 05812199 T AT05812199 T AT 05812199T AT E487484 T1 ATE487484 T1 AT E487484T1
Authority
AT
Austria
Prior art keywords
atp channel
targeting
therapeutic agents
ncca
compositions
Prior art date
Application number
AT05812199T
Other languages
English (en)
Inventor
Marc Simard
Original Assignee
Univ Maryland
Us Dept Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland, Us Dept Veterans Affairs filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE487484T1 publication Critical patent/ATE487484T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05812199T 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür ATE487484T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61075804P 2004-09-18 2004-09-18
US69827205P 2005-07-11 2005-07-11
PCT/US2005/033194 WO2006034048A2 (en) 2004-09-18 2005-09-16 Therapeutic agents targeting the ncca-atp channel and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE487484T1 true ATE487484T1 (de) 2010-11-15

Family

ID=36090529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05812199T ATE487484T1 (de) 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Country Status (9)

Country Link
US (2) US7872048B2 (de)
EP (1) EP1799227B1 (de)
JP (2) JP5085326B2 (de)
AT (1) ATE487484T1 (de)
AU (1) AU2005287090A1 (de)
CA (1) CA2580606A1 (de)
DE (1) DE602005024704D1 (de)
IL (1) IL181826A0 (de)
WO (1) WO2006034048A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2438913T3 (da) * 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
CA2571718A1 (en) * 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of an acute injury to the central nervous system
AU2005256675A1 (en) * 2004-06-23 2006-01-05 Neurotec Pharma, S.L. Compounds for the treatment of inflammation of the central nervous system
AU2005287090A1 (en) * 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
ATE486606T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
EP1884244A1 (de) * 2006-08-02 2008-02-06 Assistance Publique - Hopitaux de Paris Kalium-Kanal Liganden zur Behandlung von Diabetes und neuropsychologischen Störungen
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
WO2008098160A1 (en) * 2007-02-09 2008-08-14 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
CA3065983C (en) 2007-06-22 2022-07-26 The United States Of America As Represented By The Department Of Veterans Affairs Inhibitors of ncca-atp channels for therapy
JP5812318B2 (ja) 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ， インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
US20110263478A1 (en) * 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
KR20180123176A (ko) 2010-07-19 2018-11-14 바이오젠 체사피크 엘엘씨 글리부리드 및 다른 약물의 정맥내 투여를 위한 방법
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
EP2609914A1 (de) 2011-12-29 2013-07-03 Universitätsklinikum Hamburg-Eppendorf Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
AU2014346682B2 (en) 2013-11-06 2020-03-12 Aeromics, Inc. Novel formulations
EP4733298A1 (de) 2024-10-22 2026-04-29 Universitätsklinikum Hamburg-Eppendorf Neuartige trpm4-antagonisten und medizinische verwendung davon

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US871A (en) 1838-08-03 Mode of protectinc notes
US5725A (en) 1848-08-22 Hydraulic ram
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8809205D0 (en) * 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5166162A (en) * 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5236932A (en) * 1990-07-19 1993-08-17 E. R. Squibb & Sons, Inc. Method for treating Parkinson's disease employing quinine
CA2044853C (en) * 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
ATE199095T1 (de) * 1990-10-16 2001-02-15 Childrens Medical Center Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf)
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5916871A (en) * 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE4430212A1 (de) * 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US20010003751A1 (en) * 1995-02-22 2001-06-14 Terashita Zen-Ichi Pharmaceutical composition for treating transient ischemic attack
AUPN193095A0 (en) * 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5962645A (en) * 1996-10-04 1999-10-05 University Of Maryland Antiproliferative factor from patients with interstitial cystitis
WO1999001738A2 (en) * 1997-06-30 1999-01-14 University Of Maryland, Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
US6679859B1 (en) * 1997-10-24 2004-01-20 Alliance Pharmaceutical Corp. Amelioration of ischemic damage using synthetic oxygen carriers
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU1690399A (en) * 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6100047A (en) * 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
WO1999054706A2 (en) * 1998-04-17 1999-10-28 Univ Maryland Method of treating interstitial cystitis with recombinant hb-egf
US6613785B2 (en) * 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
US6365577B1 (en) 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
CZ20013593A3 (cs) * 1999-04-06 2002-03-13 Sankyo Company, Limited Alfa-Substituované deriváty karboxylových kyselin
WO2000069823A1 (en) * 1999-05-12 2000-11-23 Neurosearch A/S Ion channel modulating agents
KR20020047198A (ko) * 1999-09-30 2002-06-21 해피 페너 ; 해리 에이치. 페너 2세 특정 알킬렌 디아민-치환된피라졸로[1,5-ａ]-1,5-피리미딘 및피라졸로[1,5-ａ]-1,3,5-트리아진
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
KR20020063260A (ko) * 1999-12-23 2002-08-01 노파르티스 아게 당 대사 장애를 치료하기 위한 혈당강하제의 용도
EP1251840A2 (de) 2000-01-26 2002-10-30 Cedars-Sinai Medical Center Verwendung von kaliumkanalaktivatoren zur verabreichung von medikamenten an anormalen gehirnregionen und/oder bösartigen tumoren
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
CN100339132C (zh) 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10054481A1 (de) * 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US20030171407A1 (en) 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
DK2438913T3 (da) 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2571718A1 (en) 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of an acute injury to the central nervous system
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
WO2007058902A1 (en) 2005-11-11 2007-05-24 Aurogen Inc. Method for treating disease or disorder of adult central nervous system associated with tissue shrinkage or atrophy by administration of insulin
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
US7787809B2 (en) * 2007-09-10 2010-08-31 Kabushiki Kaisha Toshiba Image forming apparatus, transfer unit thereof, and method of shifting transfer rollers thereof

Also Published As

Publication number Publication date
WO2006034048A3 (en) 2008-01-17
US20110092542A1 (en) 2011-04-21
US20060100183A1 (en) 2006-05-11
JP5085326B2 (ja) 2012-11-28
EP1799227A2 (de) 2007-06-27
DE602005024704D1 (de) 2010-12-23
IL181826A0 (en) 2008-04-13
EP1799227B1 (de) 2010-11-10
AU2005287090A1 (en) 2006-03-30
EP1799227A4 (de) 2008-09-24
JP2012056966A (ja) 2012-03-22
JP2008513478A (ja) 2008-05-01
WO2006034048A8 (en) 2007-05-03
WO2006034048A2 (en) 2006-03-30
US8569377B2 (en) 2013-10-29
US7872048B2 (en) 2011-01-18
CA2580606A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ATE486606T1 (de) Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ES2340179T3 (es) Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE445415T1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
NO20065544L (no) Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
BR0315689A (pt) Alvo para terapia de dano cognitivo
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MA28279A1 (fr) Derives d&#39;indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
SE0402284D0 (sv) New heterocyclic amides
EA200970044A1 (ru) Производные пирролидина, обладающие активностью в отношении транспортера glyt1

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties